Grifols, S.A. (GRFS): Price and Financial Metrics

Grifols, S.A. (GRFS): $8.24

-0.37 (-4.30%)

POWR Rating

Component Grades








Add GRFS to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




#78 of 168

in industry

GRFS Price/Volume Stats

Current price $8.24 52-week high $13.10
Prev. close $8.61 52-week low $5.71
Day low $8.13 Volume 473,100
Day high $8.51 Avg. volume 938,248
50-day MA $7.75 Dividend yield N/A
200-day MA $7.94 Market Cap 5.67B

GRFS Stock Price Chart Interactive Chart >


  • Value is the dimension where GRFS ranks best; there it ranks ahead of 88.14% of US stocks.
  • The strongest trend for GRFS is in Quality, which has been heading up over the past 179 days.
  • GRFS ranks lowest in Quality; there it ranks in the 8th percentile.

GRFS Stock Summary

  • GRIFOLS SA's market capitalization of $6,002,354,347 is ahead of 79.03% of US-listed equities.
  • The ratio of debt to operating expenses for GRIFOLS SA is higher than it is for about 87% of US stocks.
  • With a year-over-year growth in debt of 61.16%, GRIFOLS SA's debt growth rate surpasses 84.58% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GRIFOLS SA are NARI, KLR, CDE, ROVR, and KTB.
  • Visit GRFS's SEC page to see the company's official filings. To visit the company's web site, go to

Grifols, S.A. (GRFS) Company Bio

Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories. (Source:Wikipedia)

GRFS Latest News Stream

Event/Time News Detail
Loading, please wait...

GRFS Latest Social Stream

Loading social stream, please wait...

View Full GRFS Social Stream

Latest GRFS News From Around the Web

Below are the latest news stories about GRIFOLS SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.

Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD

Now available in the U.S., this free, innovative genetic health risk service lets consumers screen for their risk of alpha1-antitrypsin deficiency (alpha-1) through a small saliva sample they can collect right at home without needing to visit a healthcare professionalAlpha-1 is the most common genetic risk factor for chronic obstructive pulmonary disease (COPD), a group of respiratory diseases affecting around 16 million Americans and the fourth-leading cause of death in the U.S.1As the leader i

Yahoo | May 11, 2023

Why Shares of Grifols Were Up Tuesday

Shares of Grifols (NASDAQ: GRFS) were up 11.1% on Tuesday afternoon, after being up as much as 13.1% earlier in the day. The pharmaceutical company, which makes plasma-derived medicines, released first-quarter earnings on Tuesday morning. The company's products range from diagnostics to detect infectious agents in blood or plasma donations, to the production of antigens used in immunoassay regents, to albumin, used to restore circulatory volume and protein loss in certain conditions.

Yahoo | May 9, 2023

Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC").

Yahoo | April 18, 2023

Are Investors Undervaluing Grifols (GRFS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Yahoo | March 15, 2023

Grifols (GRFS) Upgraded to Strong Buy: Here's Why

Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | March 7, 2023

Read More 'GRFS' Stories Here

GRFS Price Returns

1-mo 11.50%
3-mo -3.63%
6-mo -2.02%
1-year -34.55%
3-year -56.88%
5-year -60.09%
YTD -3.06%
2022 -24.31%
2021 -37.78%
2020 -20.15%
2019 28.71%
2018 -18.50%

Continue Researching GRFS

Here are a few links from around the web to help you further your research on Grifols SA's stock as an investment opportunity:

Grifols SA (GRFS) Stock Price | Nasdaq
Grifols SA (GRFS) Stock Quote, History and News - Yahoo Finance
Grifols SA (GRFS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!